Our own data in two different HD models indicate that indeed basal ERK activity is only moderately reduced, at least at the time points studied, and RB5 treatment or ERK2 overexpression significantly ameliorate cellular and behavioral phenotypes. The gene discussed is MAPK1; the disease is Huntington disease.